Related to myeloma, a phase I trial was conducted in patients with recurrent or refractory multiple myeloma with MV vectors expressing the sodium iodide symporter (NIS) in combination with cyclophosphamide or alone [148]. This evidence concerns the gene SLC5A5 and plasma cell myeloma.